MMP and IL-8 gene variations in patients diagnosed with benign prostatic hyperplasia

Variaciones de los genes MMP e IL-8 en pacientes con diagnóstico de hiperplasia prostática benigna

Background: The study aimed to determine the frequency and prognostic relevance of Matrix Metalloproteinase (MMP) and Interleukin 8 (IL-8) gene variations in patients diagnosed with benign prostatic hyperplasia (BPH). Methods: The genotypes were analyzed by restriction fragment length polymorphism (RFLP) and polymerase chain reaction (PCR), and their proportions in the patient and control groups were evaluated. Results: The TT genotype of MMP-2(-735 C/T) was more common in the patient group compared with the control group (p = 0.010). In addition, the frequency of the 5A/5A genotype of MMP-3(-1171 5A/6A) was significantly higher among the patients (p = 0.033). The proportion of individuals with the TT genotype of IL-8(-251 A/T) was also much higher in the patient group compared with the control group (p < 0.001). On one hand, compared with the controls, the patients had significantly higher frequencies of the 1G/2G-6A/6A and 2G/2G-5A/6A haplotypes of MMP-1/MMP-3 (p = 0.007 and p = 0.036, respectively), the TT-CC haplotype of IL-8/MMP-2 (p = 0.015), and the TT-6A/6A haplotype of IL-8/MMP-3 (p = 0.028). On the other hand, certain genotypes and haplotypes were identified as protective factors against BPH. Conclusions: We identified potential genetic biomarkers of BPH that may provide novel insights into disease development, progression, and prevention, and aid in the development of novel therapeutic approaches and personalized treatments.

Resumen

Antecedentes: Determinar la frecuencia y relevancia pronóstica de las variaciones génicas de Matrix Metalloproteinase (MMP) e Interleukin 8 (IL-8) en pacientes diagnosticados con hiperplasia prostática benigna (HPB). Métodos: Los genotipos se analizaron mediante polimorfismos de longitud de fragmentos de restricción (RFLP) y reacción en cadena de la polimerasa (PCR), y se evaluaron sus proporciones en los grupos de pacientes y control. Resultados: El genotipo TT de MMP-2(-735 C/T) fue más común en el grupo de pacientes en comparación con el grupo control (p = 0.010). Además, la frecuencia del genotipo 5A/5A de MMP-3(-1171 5A/6A) fue significativamente mayor entre los pacientes (p = 0.033). La proporción de individuos con el genotipo TT de IL-8(-251 A/T) también fue mucho mayor en el grupo de pacientes en comparación con el grupo control (p < 0.001). Además, en comparación con los controles, los pacientes tuvieron frecuencias significativamente más altas de los haplotipos 1G/2G-6A/6A y 2G/2G-5A/6A de MMP-1/MMP-3 (p = 0.007 y p = 0.036 respectivamente), el haplotipo TT-CC de IL-8/MMP-2 (p = 0.015) y el haplotipo TT-6A/6A de IL-8/MMP-3 (p = 0.028). Por otro lado, ciertos genotipos y haplotipos fueron identificados como factores protectores contra la HBP. Conclusiones: Identificamos posibles biomarcadores genéticos de la HBP que pueden proporcionar nuevos conocimientos sobre el desarrollo, progresión y prevención de la enfermedad, y ayudar en el desarrollo de nuevos enfoques terapéuticos y tratamientos personalizados.

Benign prostatic hyperplasia; Inflammation; Genetic variations; PCR; RFLP

Palabras Clave

Hiperplasia prostática benigna; Inflamación; Variaciones genéticas; PCR; RFLP

[1] Ozdes AA, Canturk R, Pirincci N. Urethral stones and benign prostatic hyperplasia: presentation of a rare case. Annals of Medical Research. 2025; 32: 131–134.

[2] Daryanto B, Budaya TN, Widodo, Agustriawan D, Negara EP, Effendi RA. Analysis of gene polymorphisms in benign prostate hyperplasia patients receiving combination therapy of alpha blocker (α-Blocker) and 5-Alpha Reductase Inhibitor (5-ARI). Acta Informatica Medica. 2025; 33: 54–57.

[3] Maharani R, Lestari H, Dewa PM, Yudisthira D, Amar N, Daryanto B. A comprehensive systematic review of studies on the potential of A49T and V89L polymorphism in SRD5AR2 as high susceptibility gene association with benign prostate hyperplasia and prostate cancer. Archivio Italiano di Urologia e Andrologia. 2025; 97: 13318.

[4] Wei H, Zhu C, Huang Q, Yang J, Li YT, Zhang YG, et al. Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035. BMC Urology. 2025; 25: 34.

[5] Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to Benign Prostatic Hyperplasia (BPH): AUA guideline amendment 2023. Journal of Urology. 2024; 211: 11–19.

[6] Lin L, Wang W, Shao Y, Li X, Zhou L. National prevalence and incidence of benign prostatic hyperplasia/lower urinary tract symptoms and validated risk factors pattern. The Aging Male. 2025; 28: 2478875.

[7] Inamura S, Terada N. Chronic inflammation in benign prostatic hyperplasia: pathophysiology and treatment options. International Journal of Urology. 2024; 31: 968–974.

[8] Yoo KH, Kim SK, Chung JH, Chang SG. Association of IL10, IL10RA, and IL10RB polymorphisms with benign prostate hyperplasia in Korean population. Journal of Korean Medical Science. 2011; 26: 659–664.

[9] Jurecekova J, Babusikova E, Kmetova Sivonova M, Drobkova H, Petras M, Kliment J, et al. Association between interleukin-18 variants and prostate cancer in Slovak population. Neoplasma. 2017; 64: 148–155.

[10] Wang SY, Cai Y, Hu X, Li F, Qian XH, Xia LY, et al. P. gingivalis in oral-prostate axis exacerbates benign prostatic hyperplasia via IL-6/IL-6R pathway. Military Medical Research. 2024; 11: 30.

[11] Ali SH, Abdulrahman MA, AL-Obaidi ORK. Immunological ınteractions and inflammatory changes in the pathways of benign prostatic hyperplasia and prostate cancer. Samarra Journal of Pure and Applied Science. 2025; 7: 162–169.

[12] Bahrun U, Atmanto YKAA, Nurulita A, Mangarengi F, Palinrungi MA, Bahar B. Correlation of serum interleukin-8 levels and prostate volume to the degree of lower urinary tract symptoms in patients with benign prostate enlargement: a cross-sectional study. African Journal of Urology. 2024; 30: 24.

[13] El-Chaer WK, Tonet-Furioso AC, Morais Junior GS, Souza VC, Avelar GG, Henriques AD, et al. Serum levels of matrix metalloproteinase-1 in brazilian patients with benign prostatic hyperplasia or prostate cancer. Current Gerontology and Geriatrics Research. 2020; 2020: 6012102.

[14] Life Technologies (US). PureLink genomic DNA isolation protocol. 2012. Available at: https://tools.thermofisher.com/content/sfs/manuals/purelink_genomic_man.pdf (Accessed: 08 August 2025).

[15] Mullis KB. The unusual origin of the polymerase chain reaction. Scientific American. 1990; 262: 56–61, 64–65.

[16] Botstein D, White RL, Skolnick M, Davis RW. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. American Journal of Human Genetics. 1980; 32: 314–331.

[17] Hennenberg M, Hu S, Tamalunas A, Stief CG. Genetic predisposition to benign prostatic hyperplasia: where do we stand? European Urology Open Science. 2024; 70: 154–157.

[18] Taheri M, Noroozi R, Dehghan A, Roozbahani GA, Omrani MD, Ghafouri-Fard S. Interleukin (IL)-8 polymorphisms and risk of prostate disorders. Gene. 2019; 692: 22–25.

[19] Liao CH, Wu HC, Hu PS, Hsu SW, Shen TC, Hsia TC, et al. The association of matrix metalloproteinase-1 promoter polymorphisms with prostate cancer in Taiwanese patients. Anticancer Research. 2018; 38: 3907–3911.

[20] Zhou H, Zhu X. Association between matrix-metalloproteinase polymorphisms and prostate cancer risk: a meta-analysis and systematic review. Cancer Management and Research. 2018; 10: 5247–5259.